Publisher: School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences
  • Register
  • Login

Archives of Advances in Biosciences

  • Home
  • Journal Info
    • Objectives and Scope
    • About the Journal
    • Editorial Board
    • Privacy Statement
    • Financial Policies
    • Indexing/Abstracting
    • Journal History
    • Announcements
  • Issues
    • Current
    • Archives
  • Journal Policies
    • Ethical Guidelines
    • Conflict of Interest
    • Copyright
    • Code of Publishing Ethics
    • Principles of Transparency
    • Allegations of Misconduct
    • Post-Publication Discussions and Corrections
    • Editorial Policies
    • Using Artificial Intelligence (AI)
    • Article Withdrawal
    • Complaints Process
  • Guidelines
    • Author Guidelines
    • Reviewer Guidelines
    • Journal Designer Guidelines
    • Journal Language Editor Guidelines
    • Policies of Peer Review
    • FAQ
  • Manuscript Template
    • Original Article
    • Review Article
    • Case Reports
    • Short Communication
  • Submit
  • Contact Us
Advanced Search
  1. Home
  2. Archives
  3. Vol. 6 No. 2 (2015): Spring
  4. Research/Original Articles

Vol. 6 No. 2 (2015)

April 2015

The effect of pentoxifylline drug on bax/bcl2 gene dosage expression changes following ischemic reperfusion injury in kidney

  • Mehrdad Hashemi

Archives of Advances in Biosciences, Vol. 6 No. 2 (2015), 13 April 2015 , Page 9-12
https://doi.org/10.22037/jps.v6i2.8689 Published: 2015-04-13

  • View Article
  • Download
  • Cite
  • Statastics
  • Share

Abstract

Global cerebral ischemia (GCI) and reperfusion induced apoptosis that lead to cell injury and death. The bax and bcl-2 are pro-apoptotic and anti-apoptotic genes, respectively. These genes belong to The B-cell lymphoma-2 (bcl-2) family.In this study; we assessed the effect of pentoxifylline drug on bax/bcl2 gene dosage expression changes following   ischemic reperfusion injury in kidney. In this experimental study, 20 male wistar rats were accidently divided them on two tenth group of control and treatment groups. In the control group, celiotomy was performed by ventral midline incision. The left kidney was isolated, and then both the renal artery and vein were obstructed. After 60 minutes of warm ischemia, vessel obstruction resolved and the right kidney was removed. 72 hours after reperfusion, tissue samples were taken from left kidney for histopathology. All these steps in treatment group were exactly repeated after administration of 45 mg/kg/PO pentoxifylline (3 hours before operation) and in this group treatment was continued every 12h until 3 days. In this research quantitative real-timePCR is used for the detection expression Bcl2 and  Bax genes in ischemia group and PNT drug group and  compared to  normal sample. The results showed the gene dosage ratio of Bax/bcl2 in PNT group  decline  than to  ischemia group. Therefore, the pentoxyfylline might have a role in control of apoptosis result from Ischemia- reperfusion

 

Keywords:
  • bax/bcl2 gene dosage ratio
  • Real-Time PCR
  • Ischemia
  • Kidney.
  • PDF

How to Cite

Hashemi, M. (2015). The effect of pentoxifylline drug on bax/bcl2 gene dosage expression changes following ischemic reperfusion injury in kidney. Archives of Advances in Biosciences, 6(2), 9–12. https://doi.org/10.22037/jps.v6i2.8689
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX
  • Abstract Viewed: 296 times
  • PDF Downloaded: 263 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

Developed By

Open Journal Systems

Information

  • For Readers
  • For Authors
  • For Librarians
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

Address: P.O. Box: 19395-4618, Darband St., Qods Sq.,Tehran, Iran.

Tel: +98-21-22707346

eISSN: 2783-1264

 Archives of Advances in Biosciences is an open access article under the terms of the Creative Commons Attribution -NonCommercial 4.0 International License.( CC BY-NC 4.0)

Powered by OJSPlus